MX362001B - Composición farmacéutica que comprende un agente terapéutico a base de hemoglobina modificada para tratamiento dirigido al cáncer e imagenología diagnóstica. - Google Patents

Composición farmacéutica que comprende un agente terapéutico a base de hemoglobina modificada para tratamiento dirigido al cáncer e imagenología diagnóstica.

Info

Publication number
MX362001B
MX362001B MX2015015555A MX2015015555A MX362001B MX 362001 B MX362001 B MX 362001B MX 2015015555 A MX2015015555 A MX 2015015555A MX 2015015555 A MX2015015555 A MX 2015015555A MX 362001 B MX362001 B MX 362001B
Authority
MX
Mexico
Prior art keywords
cancer
hemoglobin
therapeutic agent
pharmaceutical composition
diagnostic imaging
Prior art date
Application number
MX2015015555A
Other languages
English (en)
Other versions
MX2015015555A (es
Inventor
Lou Wong Bing
Fung Man Wai Norman
Yi Kwok Sui
Kin Wong Man
Wing Yin Man Cornelia
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of MX2015015555A publication Critical patent/MX2015015555A/es
Publication of MX362001B publication Critical patent/MX362001B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)

Abstract

La presente invención se refiere una composición farmacéutica que contiene un agente terapéutico a base de hemoglobina para tratar el cáncer. La fracción de hemoglobina puede dirigirse a las células cancerígenas y la fracción terapéutica (es decir, el agente activo/fármaco terapéutico) puede eliminar las células cancerígenas en forma eficiente. El agente terapéutico a base de hemoglobina usado en la presente invención, se puede usar en el tratamiento de varios cánceres tales como: el cáncer pancreático, la leucemia, el cáncer de cabeza y cuello, el cáncer colorectal, el cáncer pulmonar, el cáncer de mama, el cáncer hepático, el cáncer nasofaríngeo, el cáncer esofágico, el cáncer de próstata, el cáncer estomacal y el cáncer cerebral. La composición se puede usar sola o en combinación con otro(s) agente(s) terapéutico(s) tal(es) como un agente quimioterapéutico, para proporcionar un efecto sinergístico en el tratamiento del cáncer, inhibiendo la metástasis y/o reduciendo la recurrencia. El conjugado 5FU de dos tintes a base de hemoglobina y/o el conjugado 5FU de un tinte a base de hemoglobina que está siendo reivindicado, también se pueden usar en la imagenología de célula viva y en la imágenología diagnóstica.
MX2015015555A 2013-05-13 2014-05-13 Composición farmacéutica que comprende un agente terapéutico a base de hemoglobina modificada para tratamiento dirigido al cáncer e imagenología diagnóstica. MX362001B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822463P 2013-05-13 2013-05-13
US14/275,885 US9636404B2 (en) 2013-05-13 2014-05-13 Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
PCT/US2014/037749 WO2014186301A1 (en) 2013-05-13 2014-05-13 Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging

Publications (2)

Publication Number Publication Date
MX2015015555A MX2015015555A (es) 2016-05-09
MX362001B true MX362001B (es) 2019-01-03

Family

ID=51864923

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015555A MX362001B (es) 2013-05-13 2014-05-13 Composición farmacéutica que comprende un agente terapéutico a base de hemoglobina modificada para tratamiento dirigido al cáncer e imagenología diagnóstica.

Country Status (20)

Country Link
US (2) US9636404B2 (es)
EP (1) EP3001813B1 (es)
JP (1) JP6392855B2 (es)
KR (1) KR102013015B1 (es)
CN (1) CN105407911B (es)
AU (1) AU2014265659B2 (es)
BR (1) BR112015028340A2 (es)
CA (1) CA2911414C (es)
CL (1) CL2015003343A1 (es)
EA (1) EA032164B1 (es)
HK (2) HK1222574A1 (es)
IL (1) IL242422B (es)
MA (1) MA38571B1 (es)
MX (1) MX362001B (es)
MY (1) MY176175A (es)
PH (1) PH12015502536B1 (es)
SA (1) SA515370134B1 (es)
SG (1) SG11201509042YA (es)
TW (1) TWI610685B (es)
WO (1) WO2014186301A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI610685B (zh) * 2013-05-13 2018-01-11 視界全球控股有限公司 用於癌症標靶治療及診斷成像之包含經修飾的基於血紅素之治療劑的醫藥組成物
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
SG11201701565PA (en) 2014-09-03 2017-03-30 Immunogen Inc Conjugates comprising cell-binding agents and cytotoxic agents
TR201606102A2 (tr) * 2016-05-10 2016-10-21 Tolgay Tuyan Ilhan Karin i̇çi̇ uygulanan kanser tedavi̇leri̇nde oksi̇jen konsantrasyonu ölçümü yapabi̇len ve veri̇len oksi̇jen dozaji üzeri̇nde deği̇şi̇kli̇k yapmayi sağlayan ci̇haz
WO2017221185A1 (en) * 2016-06-21 2017-12-28 Therapure Biopharma Inc. Hemoglobin-targeted drug delivery for the treatment of cancer
ES2972577T3 (es) 2016-12-14 2024-06-13 Purdue Research Foundation Formación de imágenes y terapia dirigidas a la proteína de activación de fibroblastos (FAP)
US11560384B2 (en) 2017-05-04 2023-01-24 University Of Utah Research Foundation Benzonorbornadiene derivatives and reactions thereof
CN107153771B (zh) * 2017-05-17 2020-06-30 许昌学院 一种药物分子的同步控制方法及其应用
JP7387597B2 (ja) 2017-07-18 2023-11-28 ヴァーテック・バイオ・インコーポレイテッド ヘモグロビンを含む代用血液及び作製方法
WO2021013131A1 (en) * 2019-07-19 2021-01-28 Cheer Global Limited Hemoglobin-based therapeutic agents
CN114577557B (zh) * 2020-11-30 2024-06-18 中国科学院大连化学物理研究所 一种基于催化酶激活的靶向交联剂在蛋白分析中的应用
CN114605338B (zh) * 2022-05-11 2022-10-28 深圳厚存纳米药业有限公司 一种含尿嘧啶衍生物的纳米粒、核酸纳米复合物及其制备方法和用途
CN116068189A (zh) * 2023-04-07 2023-05-05 吉林重明生物科技有限公司 早期癌检测试剂及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
MC2260A1 (fr) * 1990-06-18 1993-04-26 Dow Chemical Co Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation
JP3426599B2 (ja) * 1991-11-08 2003-07-14 ヘモゾル インコーポレイテッド 薬物担体としてのヘモグロビン
CA2188565A1 (en) * 1994-04-29 1995-11-09 Meera Venkatesh Thioether compounds for use in preparing bifunctional chelating agents for therapeutic radiopharmaceuticals
US5998361A (en) * 1996-10-18 1999-12-07 University Of Maryland At Baltimore Polymerized hemoglobin
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
DE60317303T2 (de) * 2003-04-17 2008-06-19 Ezio Panzeri Hämoglobin-Konjugate
US7235639B2 (en) 2003-04-23 2007-06-26 Ezio Panzeri Hemoglobin conjugates
KR20110112301A (ko) * 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US8048856B1 (en) * 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8084581B1 (en) * 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US20130052232A1 (en) * 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
TWI610685B (zh) * 2013-05-13 2018-01-11 視界全球控股有限公司 用於癌症標靶治療及診斷成像之包含經修飾的基於血紅素之治療劑的醫藥組成物

Also Published As

Publication number Publication date
HK1223037A1 (zh) 2017-07-21
IL242422B (en) 2019-02-28
US10322180B2 (en) 2019-06-18
JP6392855B2 (ja) 2018-09-19
US9636404B2 (en) 2017-05-02
MX2015015555A (es) 2016-05-09
CN105407911B (zh) 2020-05-12
CN105407911A (zh) 2016-03-16
WO2014186301A8 (en) 2015-02-05
US20140335018A1 (en) 2014-11-13
MA38571B1 (fr) 2018-10-31
MY176175A (en) 2020-07-24
CL2015003343A1 (es) 2016-08-05
KR20160007536A (ko) 2016-01-20
PH12015502536A1 (en) 2016-02-22
TW201517921A (zh) 2015-05-16
BR112015028340A2 (pt) 2017-09-19
AU2014265659A1 (en) 2015-11-19
US20170266285A1 (en) 2017-09-21
WO2014186301A1 (en) 2014-11-20
EP3001813A4 (en) 2017-01-11
KR102013015B1 (ko) 2019-08-21
TWI610685B (zh) 2018-01-11
EP3001813A1 (en) 2016-04-06
SG11201509042YA (en) 2015-12-30
JP2016518447A (ja) 2016-06-23
HK1222574A1 (zh) 2017-07-07
EA032164B1 (ru) 2019-04-30
SA515370134B1 (ar) 2017-10-18
CA2911414C (en) 2018-09-11
AU2014265659B2 (en) 2017-03-30
EA201501065A1 (ru) 2016-04-29
MA38571A1 (fr) 2017-10-31
CA2911414A1 (en) 2014-11-20
EP3001813B1 (en) 2019-03-27
PH12015502536B1 (en) 2016-02-22

Similar Documents

Publication Publication Date Title
PH12015502536A1 (en) Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
TW201613960A (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
MX2019011494A (es) Conjugados de anticuerpo-farmaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada.
TR201807411T4 (tr) DNA-PK inhibitörleri.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
TW201613589A (en) Combination methods for treating cancers
PH12015501995A1 (en) Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment
EA201591924A1 (ru) Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
MX2016007311A (es) Metodos para tratar canceres.
WO2016080810A3 (ko) 바이구아나이드 화합물 및 이의 용도
EA201101651A1 (ru) Непрерывное введение интегриновых лигандов для лечения рака
EA201500301A1 (ru) Содержащая носитель кислорода на основе гемоглобина фармацевтическая композиция для адресного лечения рака и предотвращения рецидивов рака
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
MX2018007823A (es) Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal.
MX2016009284A (es) Construcciones dirigidas a receptor y sus usos.
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
BR112015005443A2 (pt) tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico
MX2018006776A (es) Usos de pirimido-piridazinonas para tratar el cancer.
WO2016191703A3 (en) Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer
EA201500579A1 (ru) Комбинированная терапия с использованием воласертиба
BR112018011203A2 (pt) terapia de combinação para câncer
EA201600409A1 (ru) Красный пигмент группы антрахинонов, способ получения красного пигмента штамма гриба penicillium oxalicum var. armeniaca, продукт способа, его применение, фармацевтическая композиция и способ профилактики и/или лечения онкологических заболеваний
MX2018003308A (es) Suministro localizado de agente anti-fuctactico para tratamiento del cancer.
NZ748422A (en) Heterocyclic glutaminase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration